Source: Virtual Congress 2021 – COVID-19 and management of lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
C. Bickert (Munich, Germany), K. Kahnert (Munich, Germany), D. Kauffmann-Guerrero (Munich, Germany), J. Götschke (Munich, Germany), Z. Syunyaeva (Munich, Germany), J. Behr (Munich, Germany), A. Tufman (Munich, Germany). Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: Three case studies.. 3859

Member's Comments

No comment yet.

Related content which might interest you: Consort hypersensitivity pneumonitis Source: Eur Respir J 2009; 33: 1223-1225 Year: 2009 Effect of genotype on hypersensitivity pneumonitis despite treatment. Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Clinical course in hypersensitivity pneumonitis: a review of 38 cases Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 The effects of oral corticosteroid treatment (OCS) on sequential lung function tests in a cohort of patients with acute hypersensitivity pneumonitis (AHP) Source: Virtual Congress 2020 – Clinical aspects and new treatment strategies for rare interstitial lung diseases in adults and children Year: 2020 Characterisation of patients with chronic hypersensitivity pneumonitis (CHP) - a seven year single centre experience Source: Virtual Congress 2020 – Clinical issues in granulomatous lung diseases Year: 2020 Iloprost-induced thrombocytopenia: a case proven by rechallenge Source: Eur Respir J 2010; 36: 967-969 Year: 2010 Efficacy of antifibrotics in chronic hypersensitivity pneumonitis. A 3 year real-life observational study Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report Source: Eur Respir J 2006; 28: Suppl. 50, 829s Year: 2006 Young Investigator session: Perinatal antibiotic treatment affects murine microbiota, immune responses, and pathology in models of allergic asthma and hypersensitivity pneumonitis Source: Lung Science Conference 2013 - Early origins and mechanisms of chronic lung disease Year: 2013 Employment, treatment and lung function outcomes at 1-year following diagnosis of occupational hypersensitivity pneumonitis Source: Virtual Congress 2020 – Occupational exposure as a cause of respiratory disease Year: 2020 Can persulfates cause hypersensitivity pneumonitis? A report of specific inhalation challenge test in 42 hairdressers Source: Virtual Congress 2020 – Occupational lung diseases Year: 2020 Rituximab-induced lung disease: a systematic literature review Source: Eur Respir J 2010; 35: 681-687 Year: 2010 Gemcitabine induced pulmonary toxicity in a single patient: case report Source: Eur Respir J 2006; 28: Suppl. 50, 753s Year: 2006 Hypersensitivity pneumonitis associated with the use of temozolomide Source: Eur Respir J 2009; 33: 931-934 Year: 2009 Pigeon breeder‘s hypersensitivity pneumonitis – possible antigen exposure reduction after diagnosis in the most susceptible patients Source: Annual Congress 2009 - High molecular sensitisers and biological dusts Year: 2009 Squeaks in hypersensitivity pneumonitis: prevalence and clinical correlates Source: International Congress 2019 – Pathogenesis and prognosis of interstitial lung disease of known origin Year: 2019 Standard therapy for sarcoidosis Source: Annual Congress 2005 - Biological agents in the therapy of sarcoidosis Year: 2005 Tuberculosis therapy: past, present and future Source: Eur Respir J 2002; 20: 87S-94S Year: 2002 Community-aquired pneumonia: systemic and local inflammatory response in treatment failure Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Airway administration of therapeutic antibody (tAb) confers higher protection than parenteral administration in a murine model of acute lung infection Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018